The Phase 1 clinical study was conducted in patients with facial acne
Vyome Biosciences, a clinical-stage speciality biopharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, announced that it administered the first in-human dose of its lead candidate VB 1953 in its Phase 1 clinical trial being conducted in the US to treat patients with moderate to severe facial acne.
This open-label study is designed to evaluate the safety, tolerability and pharmacokinetics of VB 1953, a topically administered gel developed to treat patients with moderate to severe acne. According to the study protocol, VB 1953 will be administered twice daily for a treatment period of 14 days following a 30-day screening period. The clinical study, which is being conducted by a CRO (Therapeutics Inc.), continues to enrol patients at a single clinical site; Therapeutics Clinical Research, in San Diego, CA.
“Microbial resistance often limits the effectiveness of treatment of moderate to severe acne. We are looking forward to evaluating VB 1953 in this patient population,” said Investigator Neal Bhatia, MD, Therapeutics Clinical Research.
“One-third of patients with moderate to severe acne do not respond to available treatment options which is due, at least in part, to microbial resistance. We believe VB 1953 can address this significant unmet need. This milestone is an important step in that direction,” said Venkateswarlu Nelabhotla, Co-founder and CEO, Vyome Biosciences.
EP News Bureau